Despite recent advances in the gene therapy field, significant challenges lie ahead for the consistent manufacturing and release of these medicines. rAAV particles are built from the folding of three major capsid proteins, VP1, VP2, and VP3, harbouring the therapeutic gene of interest. These proteins present a theoretical ratio of 1:1:10, migrating at approximately 87, 73, and 62 kDa, respectively.
To characterize rAAV purity, CE-SDS offers a state-of-the-art approach with high resolution and sensitivity and providing semi-quantitative estimate in terms of % Purity of the samples. Nevertheless, several challenges have been faced when transferring the purity assessment from SDS-PAGE to CE-SDS in terms of salt content, virus stability and impurity-nature characterization. In this webinar the different issues and the achieved solutions faced during rAAV purity characterization by CE-SDS will be discussed.
